Evidence map›Paper›PMID 31385974›Full record

ArticleNeuro-oncology practice2018

Immunogenicity of high-dose influenza vaccination in patients with primary central nervous system malignancy.

Roy E Strowd, Gregory Russell, Fang-Chi Hsu, Annette F Carter, Michael Chan, Stephen B Tatter, Adrian W Laxton, Martha A Alexander-Miller, Kevin High, Glenn J Lesser

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Roy E StrowdDepartment of Neurology and Internal Medicine Section on Hematology and Oncology, Wake Forest School of Medicine, Winston Salem, NC.
Gregory RussellDepartment of Biostatistics, Wake Forest School of Public Health, Wake Forest University Health Sciences, 1 Medical Center Boulevard, Winston Salem, NC.
Fang-Chi HsuDepartment of Biostatistics, Wake Forest School of Public Health, Wake Forest University Health Sciences, 1 Medical Center Boulevard, Winston Salem, NC.
Annette F CarterDepartment of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC.
Michael ChanDepartment of Radiation Oncology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC.
Stephen B TatterDepartment of Neurosurgery, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC.
Adrian W LaxtonDepartment of Neurosurgery, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC.
Martha A Alexander-MillerDepartment of Microbiology and Immunology, Wake Forest School of Medicine, Winston Salem, NC.
Kevin HighDepartment of Internal Medicine, Section on Infectious Disease, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem NC.
Glenn J LesserDepartment of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC.
Wake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197
6 · The paper itself

Abstract

backgroundFor cancer patients, rates of influenza-associated hospitalization and death are 4 times greater than that of the general population. Previously, we reported reduced immunogenicity to the standard-dose influenza vaccine in patients with central nervous system malignancy. In other poorly responding populations (eg, elderly patients), high-dose vaccination has improved efficacy and immunogenicity.

methodsA prospective cohort study was designed to evaluate the immunogenicity of the Fluzone

resultsTwenty-seven patients enrolled. Diagnoses included high-grade glioma (85%), CNS lymphoma (11%), and meningioma (4%). Treatment at enrollment included glucocorticoids (n = 8, 30%), radiation (n = 2, 7%), and chemotherapy (n = 9, 33%). Posttreatment lymphopenia (PTL, CD4 ≤ 200) was observed in 4 patients (15%). High-dose vaccination was well tolerated with no grade III-IV toxicity. Overall, seroconversion rates for the A/H1N1, A/H3N2, and B vaccine strains were significantly higher than in our prior study: 65% vs 37%, 69% vs 23%, and 50% vs 23%, respectively (all

conclusionsThe immunologic response to HD influenza vaccination was higher in this cohort than standard-dose influenza vaccination in our prior report. These findings mirror those in elderly patients where high-dose vaccination is the standard of care and raise the possibility of an immunosenescence phenotype.

Indexed as

gliomaimmunogenicityinfluenza vaccinationlymphopeniavaccination

Identifiers

PMID31385974
PMCPMC6655350
OpenAlexW2782101813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.